corporate overview


investors & media


investors & media

Investor Relations Home

Rigel currently has five product candidates in development: fostamatinib, an oral SYK inhibitor expected to enter Phase 3 clinical trials for ITP and a Phase 2 clinical trial for IgA Nephropathy in 2014; R348, a topical JAK/SYK inhibitor for chronic dry eye currently in Phase 2 clinical trials; R118, an AMPK activator in Phase 1; and two oncology product candidates in Phase 1 development with partners BerGenBio and Daiichi Sankyo.

Stock Quote
RIGL (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%)0.00 (0.00%)
Data as of 04/17/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
What's New
2013 Annual Report - PDF 
2013 Annual Report
Financial Tear Sheet - PDF 
Financial Tear Sheet
Recent NewsMore >>
03/06/14Rigel Announces Publication of R118 AMPK Activator Research
Initiates Phase 1 Trial for Intermittent Claudication SOUTH SAN FRANCISCO, Calif., March 6, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the American Journal of Physiology has published recent research results with its orally-bioavailable AMPK activator, R118.  The publication, entitled "Exercise performance and peripheral vascular insufficiency improve with AMPK activation…", provides strong preclinical evidence that R118 may be useful in t... 
Printer Friendly Version
03/04/14Rigel Announces Fourth Quarter and Year End 2013 Financial Results
SOUTH SAN FRANCISCO, Calif., March 4, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the fourth quarter and year ended December 31, 2013. For the fourth quarter of 2013, Rigel reported a net loss of $16.9 million, or $0.19 per share, compared to a net loss of $25.5 million, or $0.30 per share, in the fourth quarter of 2012. Weighted average shares outstanding for the fourth quarter of 2013 and 2012 were 87.4 million and 85.3 million, respe... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Most Viewed Links
Updated 04/19/14
1.Rigel Announces Publication of R118 AMPK Activator Research
2.SEC Filings
3.Current Financial Reports
4.Rigel Will Present Clinical Product Portfolio Update at J.P. Morgan Healthcare Conference
5.Rigel Announces Fourth Quarter and Year End 2013 Financial Results
* Data collected 04/11/14 - 04/18/14
Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | IR Contacts IR Contacts

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
© 2006 Rigel  |  privacy  |  disclaimer  | Follow Us On:contact us | site map |  search    Search